Literature DB >> 18091487

The role of extracellular factors in human metastatic chordoma cell growth in vitro.

Elena Ostroumov1, Christopher J Hunter.   

Abstract

STUDY
DESIGN: Human metastatic chordoma cells were isolated, and initial in vitro characterization was performed. Biochemical and physiologic changes were observed in response to pH, oxygen, and glucose.
OBJECTIVE: The extracellular microenvironment directly affects metastatic chordoma cell phenotype in vitro. SUMMARY OF BACKGROUND DATA: Chordomas are primary bone tumors that usually occur in the spine or skull. Chordomas arise from embryonic notochordal remnants along the axial skeleton, most commonly the sacrum, followed by the base of the skull and the mobile spine. Due to a high degree of resistance to radiation and chemotherapy, chordomas eventually cause death by direct growth or by metastasizing to other organs.
METHODS: Extracellular pH, oxygen, and glucose levels in the culture medium were controlled, and cell response was assessed using MTT staining, SDS-PAGE, Western blotting, tandem mass spectrometry, TUNEL, immunofluorescence, and flow cytometry.
RESULTS: In this study, we present a new chordoma cell line established from metastatic tissue and novel data characterizing some aspects of chordoma cell phenotype in different conditions in vitro. Chordoma biologic markers were expressed in the new cell line. Alkaline pH dramatically increased intracellular protein tyrosine phosphorylation, metabolic activity, and albumin accumulation in the cells, while acidic pH caused apoptosis.
CONCLUSION: The level of proliferation, apoptosis, and tyrosine phosphorylation, as well as the overall protein expression profile, strongly depended on extracellular media pH and oxygen/glucose levels. Chordoma's preferred extracellular microenvironment in vitro was rather alkaline, with an optimum at pH 8.5, and apoptotic changes were induced at acidic pH. We found that bovine serum albumin was accumulated by chordoma cells from the incubation media, and this accumulation depended on extracellular pH, with the highest accumulation at alkaline pH.

Entities:  

Mesh:

Year:  2007        PMID: 18091487     DOI: 10.1097/BRS.0b013e31815cde91

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  12 in total

1.  Establishment and characterization of a primary human chordoma xenograft model.

Authors:  I-Mei Siu; Vafi Salmasi; Brent A Orr; Qi Zhao; Zev A Binder; Christine Tran; Masaru Ishii; Gregory J Riggins; Christine L Hann; Gary L Gallia
Journal:  J Neurosurg       Date:  2012-01-27       Impact factor: 5.115

2.  Characterization and analysis of human chordoma cell lines.

Authors:  Cao Yang; Francis J Hornicek; Kirkham B Wood; Joseph H Schwab; Edwin Choy; John Iafrate; Andrew Rosenberg; G Petur Nielsen; Ramnik J Xavier; Henry Mankin; Zhenfeng Duan
Journal:  Spine (Phila Pa 1976)       Date:  2010-06-01       Impact factor: 3.468

3.  Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target.

Authors:  Wesley Hsu; Ahmed Mohyeldin; Sagar R Shah; Colette M ap Rhys; Lakesha F Johnson; Neda I Sedora-Roman; Thomas A Kosztowski; Ola A Awad; Edward F McCarthy; David M Loeb; Jean-Paul Wolinsky; Ziya L Gokaslan; Alfredo Quiñones-Hinojosa
Journal:  J Neurosurg       Date:  2011-06-24       Impact factor: 5.115

Review 4.  The biological basis for modern treatment of chordoma.

Authors:  Roberto Jose Diaz; Michael D Cusimano
Journal:  J Neurooncol       Date:  2011-03-08       Impact factor: 4.130

5.  Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma.

Authors:  Jason M Davies; Aaron E Robinson; Cynthia Cowdrey; Praveen V Mummaneni; Gregory S Ducker; Kevan M Shokat; Andrew Bollen; Byron Hann; Joanna J Phillips
Journal:  J Neurosurg       Date:  2013-11-29       Impact factor: 5.115

6.  Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin.

Authors:  Lucia Ricci-Vitiani; Daniele Runci; Quintino Giorgio D'Alessandris; Tonia Cenci; Maurizio Martini; Federico Bianchi; Giulio Maira; Louis Stancato; Ruggero De Maria; Luigi Maria Larocca; Roberto Pallini
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

7.  Chordoma and chondrosarcoma gene profile: implications for immunotherapy.

Authors:  Joseph H Schwab; Patrick J Boland; Narasimhan P Agaram; Nicholas D Socci; Tianhua Guo; Gary C O'Toole; Xinhui Wang; Elena Ostroumov; Christopher J Hunter; Joel A Block; Stephen Doty; Soldano Ferrone; John H Healey; Cristina R Antonescu
Journal:  Cancer Immunol Immunother       Date:  2008-07-19       Impact factor: 6.968

8.  Converging paths to progress for skull base chordoma: Review of current therapy and future molecular targets.

Authors:  Salvatore Di Maio; Esther Kong; Stephen Yip; Robert Rostomily
Journal:  Surg Neurol Int       Date:  2013-06-01

9.  Molecular characterization of putative chordoma cell lines.

Authors:  Silke Brüderlein; Joshua B Sommer; Paul S Meltzer; Sufeng Li; Takuya Osada; David Ng; Peter Möller; David A Alcorta; Michael J Kelley
Journal:  Sarcoma       Date:  2010-12-30

Review 10.  Novel targeted therapies in chordoma: an update.

Authors:  Salvatore Di Maio; Stephen Yip; Gmaan A Al Zhrani; Fahad E Alotaibi; Abdulrahman Al Turki; Esther Kong; Robert C Rostomily
Journal:  Ther Clin Risk Manag       Date:  2015-05-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.